Probiotics therapy for adults with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of 10 RCTs

Wang, Yan; Chen, Nan; Niu, Fangfen; Li, Yanfei; Guo, Kangle; Shang, Xue; Fenfen, E; Yang, Chaoqun; Yang, Kehu; Li, Xiuxia

doi:10.1007/s00384-022-04261-0

Cited by 17 publications

(7 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Probiotics: Probiotics can relieve bloating, intestinal gas, and IBS symptoms, and in addition, studies have shown that probiotics ( Lactobacillus , Bifidobacterium , Escherichia coli , and Streptococcus ) can significantly relieve the overall symptoms of diarrhea and IBS-D[ 126 , 127 ]. However, the role of probiotics is controversial; a small number of studies have discovered that probiotics have no effect on bloating or abdominal pain[ 128 , 129 ]. A RCT included 389 patients with IBS.…”

Section: Treatmentsmentioning

confidence: 99%

Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment

Huang¹,

Wang²,

Lv³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has several extrapulmonary symptoms. Gastrointestinal (GI) symptoms are among the most frequent clinical manifestations of COVID-19, with severe consequences reported in elderly patients. Furthermore, the impact of COVID-19 on patients with pre-existing digestive diseases still needs to be fully elucidated, particularly in the older population. This review aimed to investigate the impact of COVID-19 on the GI tract, liver, and pancreas in individuals with and without previous digestive diseases, with a particular focus on the elderly, highlighting the distinctive characteristics observed in this population. Finally, the effectiveness and adverse events of the anti-COVID-19 vaccination in patients with digestive disorders and the peculiarities found in the elderly are discussed.

show abstract

Section: Treatmentsmentioning

confidence: 99%

Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment

Huang¹,

Wang²,

Lv³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Details of many older trials that are not the focus of the current review can be found in that report. At least six systematic reviews have since been published on probiotics in IBS, examining the effects of probiotics at different levels of specificity [23 ▪ –28 ▪ ]; the considerable variation in reported effectiveness between different genera, species and strains is summarized in Table 1.…”

Section: Irritable Bowel Syndromementioning

confidence: 99%

“…These meta-analyses found that, when analysed globally across all probiotics, overall they led to beneficial impacts on global symptoms, abdominal pain and bloating in IBS patients [25 ▪ ,27 ▪ ]. However, aggregating the effects of different probiotics into a meta-analysis should be undertaken with caution as different probiotics have different characteristics that will inevitably impact on their efficacy.…”

Section: Irritable Bowel Syndromementioning

confidence: 99%

“…However, aggregating the effects of different probiotics into a meta-analysis should be undertaken with caution as different probiotics have different characteristics that will inevitably impact on their efficacy. Indeed, network meta-analyses at genus and species levels showed differential effects across specific probiotics in IBS-C and IBS-D [24 ▪ ,27 ▪ ]. At a strain level, the effects were even more specific, with only four of six probiotics meta-analysed shown to be effective for improving global symptoms ( Bacillus coagulans MTCC5260, Bifidobacterium infantis 35624, two multistrain mixtures), and only four of 12 probiotics effective for reducing abdominal pain ( B. coagulans MTCC5260, Lactobacillus rhamnosus GG, two multistrain mixtures) [23 ▪ ].…”

Section: Irritable Bowel Syndromementioning

confidence: 99%

See 1 more Smart Citation

Probiotics in irritable bowel syndrome and inflammatory bowel disease: review of mechanisms and effectiveness

Quigley

Whelan

2023

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewThe gastrointestinal (GI) microbiome has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and has been linked with irritable bowel syndrome (IBS). The aim of this article is to critically review the emerging evidence for the mechanisms and effectiveness of probiotics in the management of these conditions. Recent findingsThe GI microbiome is strongly influenced by ageing, diet and disease. Probiotics may confer health effects to the host by modulating the metabolic activities of the microbiome to propagate anti-inflammatory effects and reinforce the intestinal barrier, and are considered to be safe to use. Many short-term studies have demonstrated the effectiveness of probiotics overall in IBS, with meta-analyses demonstrating efficacy across specific strains albeit with relatively small effect sizes. Within IBD, some probiotics appear to offer clinical benefit in ulcerative colitis but strain-specific effects are unclear. Evidence for the use of probiotics in Crohn's disease remains limited.

show abstract

“…Probiotics are defined as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” [ 42 ], and the most commonly used probiotics belong to the genera Bifidobacterium and Lactobacillus [ 36 , 43 ]. Safe use of probiotics has been documented for decades, addressing a wide range of conditions, such as irritable bowel syndrome, inflammatory bowel disease, antibiotic-associated diarrhea, and respiratory tract infections [ 44 , 45 , 46 , 47 ]. In addition, multiple probiotic strains have been tested for modulation of NAFLD and T2DM with varying outcomes, and although recent meta-analyses suggest that probiotics can reduce HbA1c, fasting blood glucose and insulin resistance in T2DM patients [ 48 ] and reduce aminotransferases in NAFLD patients [ 49 ], efficacy seems to be strain dependent, suggesting that a careful preclinical screening of potential metabolically relevant targets would increase the likelihood of identifying a beneficial bacterial strain.…”

Section: Introductionmentioning

confidence: 99%

In Vitro Screening for Probiotic Properties of Lactobacillus and Bifidobacterium Strains in Assays Relevant for Non-Alcoholic Fatty Liver Disease Prevention

et al. 2023

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial metabolic disorder that poses health challenges worldwide and is expected to continue to rise dramatically. NAFLD is associated with metabolic syndrome, type 2 diabetes mellitus, and impaired gut health. Increased gut permeability, caused by disturbance of tight junction proteins, allows passage of damaging microbial components that, upon reaching the liver, have been proposed to trigger the release of inflammatory cytokines and generate cellular stress. A growing body of research has suggested the utilization of targeted probiotic supplements as a preventive therapy to improve gut barrier function and tight junctions. Furthermore, specific microbial interactions and metabolites induce the secretion of hormones such as GLP-1, resulting in beneficial effects on liver health. To increase the likelihood of finding beneficial probiotic strains, we set up a novel screening platform consisting of multiple in vitro and ex vivo assays for the screening of 42 bacterial strains. Analysis of transepithelial electrical resistance response via co-incubation of the 42 bacterial strains with human colonic cells (Caco-2) revealed improved barrier integrity. Then, strain-individual metabolome profiling was performed revealing species-specific clusters. GLP-1 secretion assay with intestinal secretin tumor cell line (STC-1) found at least seven of the strains tested capable of enhancing GLP-1 secretion in vitro. Gene expression profiling in human biopsy-derived intestinal organoids was performed using next generation sequencing transcriptomics post bacterial co-incubation. Here, different degrees of immunomodulation by the increase in certain cytokine and chemokine transcripts were found. Treatment of mouse primary hepatocytes with selected highly produced bacterial metabolites revealed that indole metabolites robustly inhibited de novo lipogenesis. Collectively, through our comprehensive bacterial screening pipeline, not previously ascribed strains from both Lactobacillus and Bifidobacterium genera were proposed as potential probiotics based on their ability to increase epithelial barrier integrity and immunity, promote GLP-1 secretion, and produce metabolites relevant to liver health.

show abstract

Probiotics therapy for adults with diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis of 10 RCTs

Cited by 17 publications

References 51 publications

Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment

Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment

Probiotics in irritable bowel syndrome and inflammatory bowel disease: review of mechanisms and effectiveness

In Vitro Screening for Probiotic Properties of Lactobacillus and Bifidobacterium Strains in Assays Relevant for Non-Alcoholic Fatty Liver Disease Prevention

Contact Info

Product

Resources

About